Kornimate/medical-research-clean huggingface dataset:
the clinical efficacy of non-steroidal anti-inflammation drugs in patients with benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia

Summary: non-steroidal anti-inflammation drugs can effectively reduce the lower urinary tract symptoms from benign prostatic hyperplasia


Eligibility criteria:
inclusion criteria: * who had the treatment of bph with alpha-1 blockers for more than 3 months * who have the ipss(international prostatic symptom score) \>= 15 * who have the maximum flow rate(qmax) \ 150ml * who have the ppbc(patient's perception of bladder condition) \>= 3 (the ppbc was assessed by the use of a six point ordered categorical scale(1-6 point). the higher score means the higher bother) * who had the psa level \< 4 ng/ml within 6 months (but, the patient who are revealed not to have prostate cancer by prostate biopsy can be included even if he had psa level of 4-10 ng/ml) * who underwent the transrectal ultrasound of prostate within 6 months * who can understand this study and can give the informed consent exclusion criteria: * who had regular intake of 5-alpha reductase inhibitor or nsaid within 6 months before screening * who have peptic ulcer and/or asthma * who have urologic malignancies such as prostate cancer and bladder cancer * who have urethral strictures, large bladder diverticuli, and bladder neck contractures * who had surgical treatment for bph * who have histories of bladder and/or urethra * who have serum psa level more than 10 ng/ml * who have histories of orthostatic hypotension * who have serum creatinine level more than 2.0 mg/dl * who have serum alt and/or ast level more than 1.5 times of normal upper limit * who have heart failure * who have histories of bacterial prostatitis within 1 year * who have histories of active urinary tract infection within 1 month * who have histories of the biopsy of bladder and prostate within 1 month * who are unable to void * who use pads because of incontinences * who have hypersensitivities for alpha blockers that include quinazoline, nsaid, aspirin, sulfonamide * who have histories of unstable angina, myocardial infarction, and cerebrovascular accident within 6 months * who have neurogenic bladder due to multiple sclerosis, parkinson's disease, spinal injuries and etc. * who have thinking disturbances * who have histories of abuses of alcohol and/or other drugs * who seem to be not fit to this study by the decision of investigators

Keywords: cyclooxygenase 2 inhibitors alpha blockers treatment outcome
bioimpedance for ortho trauma

Conditions: Trauma Injury

Summary: patients with high-energy extremity trauma will undergo imaging with an eit device in the emergency department, operating room, orthopaedic clinic, and in-patient hospital rooms. the eit device is an electrical impedance tomography system.


Eligibility criteria:
inclusion criteria: * age 18 years or older * high energy closed extremity fracture * provision of informed consent exclusion criteria: * metatarsal fractures * injury to both lower extremities precluding contralateral imaging * presence of an implanted electronic device (e.g. pacemaker, vagal stimulator, deep brain stimulator) or electrodes or electrical wires. * currently pregnant, potentially pregnant, or lactating women

Keywords: orthopedics extremity fracture
certolizumab pegol in subjects with adult onset active and progressive psoriatic arthritis

Conditions: Arthritis, Psoriatic

Summary: phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol (czp) in subjects with adult onset active and progressive psoriatic arthritis (psa).


Eligibility criteria:
inclusion criteria: * diagnosis of adult-onset psoriatic arthritis (psa) of at least 6 months' duration as defined by the classification criteria for psoriatic arthritis (caspar criteria) * active psoriatic skin lesions or a documented history of psoriasis * active arthritis with ≥ 3 tender joints at screening and baseline, ≥ 3 swollen joints at screening and baseline and fulfilling at least 1 of the following 2 criteria during the screening period: 1. erythrocyte sedimentation rate (esr) (westergren) ≥ 28 mm/hour 2. c-reactive protein (crp) \> upper limit normal (uln) * failure to 1 or more treatment with disease-modifying anti-rheumatic drugs (dmards) exclusion criteria: * diagnosis of any other inflammatory arthritis or known diagnosis of fibromyalgia * exposure to more than 1 tumor necrosis factor α (tnfα) antagonist or to more than 2 previous biological response modifiers for psa or psoriasis * any non-biological systemic treatment of psoriasis; phototherapy; topical agents * history of chronic or recurrent infections * high risk of infection * live vaccination within the 8 weeks prior to baseline * concurrent malignancy or a history of malignancy * class iii or iv congestive heart failure - new york heart association (nyha) * demyelinating disease of the central nervous system * clinically significant laboratory abnormalities

Keywords: certolizumab pegol cimzia
blockade efficacy of buprenorphine/naloxone for opioid dependence

Conditions: Opioid-Related Disorders

Summary: buprenorphine, a treatment for opioid dependence, can be mixed with naloxone, to limit abuse potential. the purpose of this study is to examine the effectiveness of buprenorphine/naloxone that is given at less than daily intervals, in order to prevent withdrawal symptoms associated with stopping opioid abuse.

buprenorphine and naloxone are often combined to decrease withdrawal symptoms in opioid dependent individuals. buprenorphine/naloxone is usually given daily to individuals who are attempting to stop opioid abuse; however, research suggests that individuals may be more inclined to take medication if it is given in less than daily intervals. the purpose of this study is to examine the opioid blockade effects of buprenorphine/naloxone that is administered in less than daily doses to opioid dependent individuals. this study will last 11 weeks. participants will stay in a residential research unit for the duration of the study. participants will be randomly assigned to receive different doses of daily, sublingual buprenorphine/naloxone. after a minimum of 2 weeks on each dose, participants will undergo challenge sessions on each weekday for 1 week (monday through friday). challenge sessions will consist of increasing doses of intramuscular hydromorphone. during the challenge session week, buprenorphine/naloxone will be given only on monday; a placebo will be given the rest of the week. challenge sessions will examine the blockade effects of buprenorphine/naloxone at 2, 26, 50, 74, and 98 hours after the last active dose of buprenorphine/naloxone.

Eligibility criteria:
inclusion criteria: * meets diagnostic criteria for opioid dependence * qualifies for opioid substitution treatment (e.g., methadone) exclusion criteria: * significant psychiatric or physical disorder

Keywords: opioid dependence
convalescent plasma in covid-19 elderly patients

Conditions: COVID-19

Summary: the trend of the spread of the covid-19 pandemic demonstrates in lombardy, starting from 28.03.2020, a slowdown in the exponential phase of infections and the probable reaching of a plateau phase. however, a marked increase in infections was observed in the so-called "protected structures" such as nursing homes (rsa), both in health staff and in the residents of such facilities. the observed percentage of lethality, according to the more recent data provided by the national institute of health, is very high especially among residents. for these reasons, the city hospital (asst) of mantua , already involved in the use of hyperimmune plasma as a therapy for covid-19, designed this study in order to evaluate rsa patients and to identify the cases eligible for this treatment.

for a detailed description of the study, see the attached protocol

Eligibility criteria:
inclusion criteria: * elderly patients (\> 65 years old) with sars-cov-2 rt-pcr positivity on nasal swab or score higher than 5 with the following characteristics: * new onset or worsening of recently onset respiratory symptoms (\<10 days); * radiological imaging (ct, x-ray, ultrasound) of bilateral pulmonary opacities not fully explained by pleural effusion, pulmonary or lobar atelectasis, pulmonary nodules; * respiratory failure (spo2 \<95%) not fully explained by heart failure or water overload (after excluding hydrostatic causes of edema in the absence of risk factors by objective assessment, for example ultrasound); * patients who have signed informed consent. exclusion criteria: * new onset or worsening of respiratory symptoms that began more than 10 days ago; * patients with proven hypersensitivity or allergic reaction to plasma, blood products or immunoglobulins; * manifest desire not to be included in the research protocol.
patient support during surgical abortion

Conditions: Surgical Abortion

Summary: this study will be a non-blinded randomized controlled trial (rct) of women presenting for abortion at \<13 6/7 weeks. women will be randomized either to receive support by a trained abortion doula (intervention) or to have standard procedure (control) during the abortion procedure. the investigators hypothesize that women who receive doula support during a first trimester abortion will report less pain during the abortion procedure compared to women who do not receive abortion doula support.


Eligibility criteria:
inclusion criteria: * aged \> 18 years * gestational age by sonogram \< 13 6/7 weeks gestation * desires pregnancy termination * ability to understand the study and give informed consent * ability to read and comprehend informed consent document in english exclusion criteria: * aged \< 18 years * gestational age by sonogram \> 13 6/7 weeks gestation * inability to understand the study and give informed consent * inability to read and comprehend informed consent document in english

Keywords: doula abortion pain support
evaluation of impedance cardiography for assessing hemodynamic shifts in patients with la-nsclc during treatment.

Conditions: Non-small Cell Lung Cancer; Cardiac Toxicity

Summary: this study aimed to investigate the role of impedance cardiography (icg) in evaluating hemodynamic changes during the 6-minute walk test (6mwt) in patients with locally advanced non-small cell lung cancer (la-nsclc) who underwent combined concurrent chemoradiotherapy (ccrt) and immunotherapy. additionally, it sought to analyze the predictive significance of cardiac parameters to both treatment toxicity and survival prognosis.


Eligibility criteria:
inclusion criteria: 1. had untreated histologically or cytologically confirmed nsclc 2. be between the age of 18 and 75 3. had unresectable stage iiia-iiic disease, as defined by the ajcc 8th edition staging system 4. had an eastern cooperative oncology group (ecog) performance status score of 0\~1 5. had adequate bone marrow function (neutrophil count ≥1.5x109/l, hemoglobin concentration ≥90 g/l, platelet ≥100x109/l), kidney function (serum creatinine clearance ≥50 ml/min) and liver function (serum bilirubin ≤1.5 times upper limit of normal (uln), aspartate transaminase (ast) and alanine transferase (alt) ≤2.5 uln) 6. had a forced expiratory volume in 1 second (fev1) of ≥0.8l. exclusion criteria: 1. mixed small cell and nsclc histology 2. life expectancy lower than 12 weeks 3. history of another primary malignancy 4. poorly controlled intercurrent illness 5. female in pregnancy or breast-feeding and any situation not suitable for this study judged by researchers 6. patients with contraindications to 6mwt, including unstable angina pectoris or myocardial infarction within the past month, systolic blood pressure (sbp) over 180mmhg, diastolic blood pressure (dbp) over 100mmhg, muscle strength below grade 3, and severe spasm.

Keywords: non-small cell lung cancer impedance cardiography concurrent chemoradiotherapy
effect of extra virgin olive oil addition in the diet of women with gestational diabetes mellitus (olidiag)

Conditions: Gestational Diabetes

Summary: gestational diabetes mellitus (gdm) is associated to adverse maternal and neonatal outcomes. the aim of this study is to address whether the addition of extra virgin olive oil to the diet of women with gdm improves maternal triglyceridemia and reduces insulin requirement and diagnosis of diabetes at postnatal reclassification.

this study is a randomized trial in which 1200 pregnant women at gdm diagnosis from 16 health care centers will be recruited and randomized in two parallel arms: 1 world health organization (who)-diet supplemented with 3 tablespoons of extra virgin olive oil (intervention group, n=600); 2. who-diet with no extra virgin olive oil supplementation (control group, n=600). expected results: the investigators expect that the intervention will contribute to improve maternal lipid profile, reduce insulin requirement and reduce maternal diagnosis of diabetes at postpartum reclassification. thus, this study is expected to identify maternal beneficial effects of this dietary intervention.

Eligibility criteria:
inclusion criteria: * gdm (diagnosis criteria of the latin american society of diabetes (alad) and argentine society of diabetes (sad): fasting plasma glucosa \> 100 mg/dl, p75 oral glucose tolerance test-2 h plasma glucose \> 140 mg/dl) exclusion criteria: * multiple pregnancy * pregestational diabetes (type 1 or type 2) * bariatric surgery * infectious diseases

Keywords: gdm extra virgin olive oil lipid profile insulin requirement postpartum reclassification
efficacy and safety of itolizumab in covid-19 complications

Conditions: Acute Respiratory Distress Syndrome; Cytokine Release Syndrome; Covid19

Summary: randomized, parallel group, active controlled trial

this is a multi-centric, open label, two arm randomized, phase 2 study. all eligible patients entering into the study will be randomized in 2:1 ratio to receive the treatment a (best supportive care + itolizumab) / b (best supportive care) respectively. each patient will undergo the treatment based on their assigned treatment for a month along with battery of tests that includes, but not limited to, cytokines and chemokine, along with recording of tlc; dlc, anc, alc; platelet count; s. creatinine; t.bilirubin; morning vitals -pulse, bp, rr; temperature, pao2/fio2, map, gcs. as itolizumab is an investigational drug, the benefit to covid-19 patients experiencing complications such as cytokine release syndrome is not known. however, findings from this study may be beneficial to the society at a large at the national and international level.

Eligibility criteria:
key inclusion criteria: 1. male or female adults above 18 years (not tested in children yet) 2. informed consent for participation in the study 3. virological diagnosis of sars-cov2 infection (pcr) 4. hospitalized due to clinical/instrumental diagnosis of covid-19 infection 5. oxygen saturation at rest in ambient air ≤94% 6. patients who are in moderate to severe ards as defined by pao2/fio2 ratio of \< 200 key exclusion criteria: 1. known severe allergic reactions to monoclonal antibodies 2. active tuberculosis (tb) infection 3. history of inadequately treated tuberculosis or latent tuberculosis 4. in the opinion of the investigator,progression to death is highly probable, irrespective of the provision of treatments 5. have received oral anti-rejection or immune-suppressive drugs within the past 6 months 6. participating in other drug clinical trials (participation in covid-19 anti-viral trials may be permitted if approved by medical monitor) 7. pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination 8. patients with known history of hepatitis b, hepatitis c or hiv 9. absolute neutrophils count (anc) \<1000 / mm3 10. platelets \<50,000 / mm3 11. absolute lymphocyte count (alc): \<500/mm3
carrageenan for the prevention of oral hpv infection

Conditions: Human Papilloma Virus

Summary: this is a placebo-controlled, triple-blind randomized clinical trial (rct) designed to evaluate the feasibility of conducting a larger multicentric rct investigating the effect of a carrageenan mouthwash on oral hpv infection. eligible participants will complete a single in-person visit at baseline, filling out a questionnaire on their electronic device and giving an oral rinse sample for hpv testing. they will receive an adequate supply of mouthwash and instructions on its use. they will subsequently be followed up for up to six months. every two weeks, participants will fill out a follow-up questionnaire on mouthwash use and sexual activities and self-collect oral rinse sample to be returned by mail.


Eligibility criteria:
inclusion criteria: * aged between 18 and 45 years old * sexually active and have had oral sex in the past month * will be residing in montreal for the next six (6) months after study enrolment exclusion criteria: * previous vaccination against hpv * previous cancer of the mouth or throat

Keywords: oral hpv infection mouthwash carrageenan
the relationship between gait and severity of femoroacetabular impingement

Conditions: Femoroacetabular Impingement

Summary: in this study, the spatiotemporal gait parameters of symptomatic femoroacetabular impingement (fai) patients scheduled for hip arthroscopy are evaluated. radiological measurements, including the alpha angle (aa), lateral center-edge angle (lcea), and kellgren-lawrence (kl) osteoarthritis classification, are recorded from patient files. the relationship between these radiological measurements and walking parameters is assessed. additionally, the spatiotemporal gait parameters of fai patients are compared with those of a healthy control group. walking assessments provide valuable insights into how femoroacetabular impingement (fai) affects movement and aid in evaluating treatment outcomes. research indicates that individuals with fai experience reduced hip motion and slower walking speeds. by analyzing spatiotemporal gait parameters-such as gait velocity, cadence, step length, and vertical center of mass-the impact of fai on walking can be better understood, leading to the development of targeted treatment strategies. the goal is to explore the correlation between these gait parameters and imaging-based fai characteristics in affected individuals.

patients and control groups are compared using the paired samples t-test for parametric data and the wilcoxon signed ranks test for nonparametric data. the relationship between gait parameters and imaging-based fai characteristics is examined by calculating the pearson correlation coefficient (r) for parametric data and the spearman rank correlation coefficient (rho) for non-parametric data.

Eligibility criteria:
inclusion criteria: * patients with femoroacetabular impingement scheduled for hip arthroscopy exclusion criteria: * severe hip osteoarthritis * hip dysplasia * previous ipsilateral and/or contralateral hip surgery, * any orthopedic or neurologic pathology that may affect gait patterns
primary care validation in french of a single-question screening test for unhealthy alcohol use.

Conditions: Unhealthy Alcohol Use

Summary: unhealthy alcohol use (uau) is a very important public health concern. in france uau is the second cause of avoidable death after tobacco smoking. in 2014, 31% of the french adult population presented with unhealthy alcohol use. primary care practitioners have access to validated questionnaires in french such as the alcohol use disorder identification test (audit) and the fast alcohol consumption evaluation (face). these tests are not often used because of their length. in 2009 a study by smith et al in the usa compared a single question with the audit-c (a short version of the audit). the single question was "how many times in the past year have you had x or more drinks in a day?" where x is 7 for men and 6 for women. this study found that the single question had a comparable sensitivity and a specificity, respectively 81,8% and 79,3%. the aim of the study is to validate this question in french. first the question has been translated from english to french following the who method. the aim of the present study is to validate the french translation by comparing it with the audit and the face. a questionnaire will be given to patients with inclusion criteria in general practitioners waiting rooms (15 different locations). this questionnaire will be composed of the single question, followed by the audit and face, and three socio-demographic questions. the questionnaire will be anonymous.


Eligibility criteria:
inclusion criteria: * consulting in a general practitioner's office * over 18 years old exclusion criteria: * less than 18 years old * pregnant women or breast-feeding mothers * people under legal protection
embryo transfer: embryo expulsion and outcome

Conditions: Infertility

Summary: according to the studies, about 80% of patients undergoing in vitro fertilization/intracytoplasmic sperm injection (ivf/icsi) reach to the embryo transfer process, but only a few of them become pregnant. the cause of this difference can be due to some factors such as the endometrial receptivity, quality of transferred embryos and embryo transfer technique. retained or expelled embryo(s) following embryo transfer is (are) one of the factors which may be effective on outcome. the purpose of this randomized clinical trial study is "lowering embryo expulsion following embryo transfer to improve outcome."

a total of 134 infertile women who undergo ivf or icsi treatment cycle at royan institute (infertility and reproductive medicine research centre) will enroll in this prospective randomized clinical trial study and will randomly be divided into two groups of 67 patients. this study has been approved by royan ethics committee and written consent will be obtained from each patient. the patients with frozen-thawed embryo transfer cycle and those with oocyte donation cycle, the women with uterine abnormality and the subjects with submucosal and intramural myoma, will be excluded from this study. after the ovarian stimulation and oocyte retrieval, the ivf and intracytoplasmic sperm injection (icsi) procedures will be performed to produce the embryos. embryo transfer will be done only by one skilled physician. the patients will be divided into two groups of a and b by computerized randomly chart. in group a, the prevention technique of embryo expulsion will be carried out following embryo transfer, but no intervention will be performed in group b (control group). after 2 weeks, the patients will be tested for serum β-hcg for assessing the pregnancy. the clinical pregnancy will be clarified by the number of women with gestational sacs on transvaginal sonography at 4-6 weeks of gestation. in the calculation of implantation, the number of gestational sacs will be considered.

Eligibility criteria:
inclusion criteria: * women undergoing ivf or icsi treatment cycle * patients with "long or antagonist" protocol exclusion criteria: * the patients with frozen-thawed embryo transfer cycle * those with oocyte donation cycle * the women with uterine abnormality * the women with submucosal and intramural myoma * who does not have good-quality embryos appropriate

Keywords: embryo transfer ivf/icsi embryo expulsion